drugset
drugset / Trial / NCT05667623

To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With AD

NCT05667623 ↗

Phase 3 Completed 270 enrolled Otsuka Beijing Research Institute
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a multinational (China and Korea), multicenter, randomized, double-blind, vehicle-controlled, parallel-group, comparison trial to demonstrate the superiority of 1% OPA-15406 ointment to the vehicle in adult AD subjects.

Timeline

Start
2023-02-06
Primary completion
2024-06-17
Completion
2024-11-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Difamilast Small molecule 1 % Topical
Subject Difamilast Small molecule 10000 mg/m2 Topical

Indications

atopic eczema